NATA is funding two Research Challenge consortia to address critical issues in the delivery and manufacture of NATs: TransNAT and BioManNAT. By tackling these challenges, we can unlock the full therapeutic potential of NATs to bring health benefits to patients.
Delivery Challenge
NATA and LifeArc have awarded £8M to the Delivery Challenge Consortium led by Professor Matthew Wood, University of Oxford, to develop new methods for cell-specific delivery of oligonucleotide therapies.
Manufacturing Challenge
NATA has awarded £6M to the Manufacturing Challenge Consortium led by Professor Nick Turner, Manchester Institute of Biotechnology, University of Manchester, to develop novel, sustainable manufacturing methods using enzymatic biocatalysis.
